Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • In vivo antitumor efficacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

    Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

     

    Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

    Cell death dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

    Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

     

     

    BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

     

     

    Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot. 

    Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Targets
Bcl-2 [1]
(Cell-free assay)
0.22 μM(Ki)
In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS-45 M{DVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rFV2lEPTB;MD6wNFAxOzF5IN88US=> NEmzO4xUSU6JRWK=
SK-MEL-30 NH7CcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMECwN|U2KM7:TR?= NXPGWo1KW0GQR1XS
NALM-6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED5So5KSzVyPUCuNFAxOzV4IN88US=> MV7TRW5ITVJ?
KYSE-450 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTrS2JKSzVyPUCuNFAxPDZ7IN88US=> NHLlUZlUSU6JRWK=
BHY MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLsRpZKSzVyPUCuNFAxPjBzIN88US=> NWHjVW1EW0GQR1XS
GR-ST MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny4TWM2OD1yLkCwNFY1QCEQvF2= MlWzV2FPT0WU
786-0 NVPzOVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLBeVFoUUN3ME2wMlAxODd5NjFOwG0> NFLneGRUSU6JRWK=
C-33-A M2\S[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn0TWM2OD1yLkCwNFg1QCEQvF2= M33YVnNCVkeHUh?=
BHT-101 NIjnUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMECxNFYh|ryP NIDJ[GFUSU6JRWK=
EB2 NXHqPI5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPkPGFyUUN3ME2wMlAxOTF6IN88US=> M33GTnNCVkeHUh?=
G-361 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zEUGlEPTB;MD6wNFEzPCEQvF2= M1jPNnNCVkeHUh?=
KE-37 NHjhPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMECxNlgh|ryP NIrOR2hUSU6JRWK=
MHH-PREB-1 NV71RY86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\BPI1KSzVyPUCuNFAyPCEQvF2= M4DMSHNCVkeHUh?=
MCF7 NGC3XJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfFclI{UUN3ME2wMlAxOTV7IN88US=> NFK5N|RUSU6JRWK=
LOUCY M4f3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjReFdnUUN3ME2wMlAxOTd3IN88US=> NILY[5pUSU6JRWK=
EW-7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMECxO|Uh|ryP NIjifGlUSU6JRWK=
KYSE-510 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS2TWM2OD1yLkCwNlM{KM7:TR?= MlnBV2FPT0WU
SK-MEL-3 M4TsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPhdYVpUUN3ME2wMlAxOjZ2IN88US=> M3rJT3NCVkeHUh?=
HAL-01 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P2dWlEPTB;MD6wNFI6PyEQvF2= MorWV2FPT0WU
HCC2998 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13LNmlEPTB;MD6wNFM{PSEQvF2= M2XQOXNCVkeHUh?=
A375 NVPUfY45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvtTWM2OD1yLkCwN|Uh|ryP MUXTRW5ITVJ?
MZ7-mel MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMECzPVkh|ryP MUnTRW5ITVJ?
SH-4 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHyW5NnUUN3ME2wMlAxPDF5IN88US=> M1TCU3NCVkeHUh?=
HT-144 MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEC0N{DPxE1? NGnycnVUSU6JRWK=
KYSE-140 M4jXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXew[FN2UUN3ME2wMlAxPDN3IN88US=> Mm\zV2FPT0WU
PSN1 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEC0Olch|ryP MofuV2FPT0WU
COLO-679 NUfDR3Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrENG1KSzVyPUCuNFA1QThizszN M2Hvc3NCVkeHUh?=
SW620 M2Poemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vlbmlEPTB;MD6wNFUyOSEQvF2= NVrDbVN7W0GQR1XS
HGC-27 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W3bmlEPTB;MD6wNFUzPCEQvF2= MX;TRW5ITVJ?
IGROV-1 NUGzbXBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf0Z3BKUUN3ME2wMlAxPiEQvF2= NEjKcWFUSU6JRWK=
IGR-1 M2DQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEC2NFEh|ryP MonGV2FPT0WU
EW-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rNW2lEPTB;MD6wNFY2OSEQvF2= NHjpNINUSU6JRWK=
769-P MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorsTWM2OD1yLkCwOlc5KM7:TR?= NUKwS3k3W0GQR1XS
HN M3zWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfmXG9KSzVyPUCuNFA3PzlizszN M3jjS3NCVkeHUh?=
SIG-M5 M4W5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH4TWM2OD1yLkCwO|Eh|ryP MoLTV2FPT0WU
IST-MEL1 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LIVWlEPTB;MD6wNFgyQCEQvF2= MXrTRW5ITVJ?
ST486 NIHveIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrZTWM2OD1yLkCwPFI2KM7:TR?= MlflV2FPT0WU
ES7 NUDlT4hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7uXpRQUUN3ME2wMlAxQDR4IN88US=> NH\sTIlUSU6JRWK=
GAK M4S3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMEC4OFgh|ryP NV7SOI5qW0GQR1XS
BB30-HNC M3qxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEC4OVgh|ryP NYexbVBWW0GQR1XS
IPC-298 NWjRdYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLJTWM2OD1yLkCwPVI4KM7:TR?= NHnySI5USU6JRWK=
NKM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEC5O|Ih|ryP Mnr3V2FPT0WU
RKO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fr[GlEPTB;MD6wNVA1PCEQvF2= Ml[4V2FPT0WU
ACN NV\DbZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEGxN|Eh|ryP MVnTRW5ITVJ?
SW1417 NFzyR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHKOWJqUUN3ME2wMlAyOjJ3IN88US=> NW\iUohPW0GQR1XS
SR MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEGyN|Uh|ryP NWrNcm96W0GQR1XS
SNG-M M2\J[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7HNXlNUUN3ME2wMlAyOzF5IN88US=> NYPoTY1xW0GQR1XS
CAL-12T NF63bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\SRWlEPTB;MD6wNVM1PiEQvF2= MWXTRW5ITVJ?
HSC-3 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\JRmlEPTB;MD6wNVM2PSEQvF2= Ml[zV2FPT0WU
DOHH-2 NYTZV2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEG0NVIh|ryP MUHTRW5ITVJ?
NB69 NGnIPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTSTWM2OD1yLkCxOVY2KM7:TR?= NWTxOGdSW0GQR1XS
LC-2-ad M37K[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvwUFB[UUN3ME2wMlAyPThzIN88US=> M3ewNnNCVkeHUh?=
RVH-421 NF;rVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHuOlJKSzVyPUCuNFE3PzRizszN NFPlUINUSU6JRWK=
TGW NV\scY85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW4TWM2OD1yLkCxO|M6KM7:TR?= MlHYV2FPT0WU
HCC1569 M3XQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfkfIZEUUN3ME2wMlAyPzl5IN88US=> MmfEV2FPT0WU
CAL-85-1 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEG4N|Ih|ryP MnjIV2FPT0WU
RPMI-8402 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzGTWM2OD1yLkCxPFU5KM7:TR?= NIOxeoFUSU6JRWK=
THP-1 NGX0[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPISllKSzVyPUCuNFE6QThizszN M4TXe3NCVkeHUh?=
ONS-76 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGewO|dKSzVyPUCuNFIxOzZizszN NWWwd2NpW0GQR1XS
A2780 M3LrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfXTWM2OD1yLkCyNFc6KM7:TR?= NFHYZ5BUSU6JRWK=
RPMI-2650 NUexOZVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O5NmlEPTB;MD6wNlI6PiEQvF2= MV3TRW5ITVJ?
MEL-HO NVHtV5Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\xPGlEPTB;MD6wNlM1QCEQvF2= MVHTRW5ITVJ?
MC-CAR NELMW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITLPFZKSzVyPUCuNFI{PTZizszN MmjVV2FPT0WU
HSC-2 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGezN|VKSzVyPUCuNFI1PjZizszN MlzSV2FPT0WU
MEL-JUSO M4PyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TRfWlEPTB;MD6wNlQ4OyEQvF2= NUTyN4ltW0GQR1XS
CAL-62 NWe0NnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW1d|VKSzVyPUCuNFI3ODJizszN MUPTRW5ITVJ?
DMS-273 NVvWe5A1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfjXnRrUUN3ME2wMlAzQDR5IN88US=> M3XFTXNCVkeHUh?=
S-117 M{PvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLHbZhKSzVyPUCuNFI6ODZizszN M4LhUnNCVkeHUh?=
SUP-T1 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[2TWM2OD1yLkCyPVQ6KM7:TR?= NIfqPZpUSU6JRWK=
MZ2-MEL MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof4TWM2OD1yLkCyPVU6KM7:TR?= NGrPZopUSU6JRWK=
KYSE-270 NIPMdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEK5O|Yh|ryP MmTCV2FPT0WU
CMK MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL6TWM2OD1yLkCzNFI{KM7:TR?= NYLCbJFPW0GQR1XS
8505C M3vZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPQW5FNUUN3ME2wMlA{ODRizszN NFL5cI1USU6JRWK=
NUGC-3 NXGxcXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGntPJVKSzVyPUCuNFMxPDhizszN MWrTRW5ITVJ?
A101D MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXqTWM2OD1yLkCzNFU2KM7:TR?= NIrXTI5USU6JRWK=
G-401 NVS1PXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEOwPVMh|ryP NGfZRY5USU6JRWK=
OVCAR-8 M2XZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\idGlEPTB;MD6wN|ExPyEQvF2= NFL2TG9USU6JRWK=
IMR-5 NFe4fYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DYSGlEPTB;MD6wN|I1PCEQvF2= MWDTRW5ITVJ?
DoTc2-4510 M{TsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrIVpZtUUN3ME2wMlA{Ozl|IN88US=> M3SzfXNCVkeHUh?=
HOS NEjIU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLnTWM2OD1yLkCzOFc{KM7:TR?= MoGzV2FPT0WU
HEC-1 M3vNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLKTWM2OD1yLkCzOlgh|ryP MVjTRW5ITVJ?
SW756 NUP2VIVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXPTWM2OD1yLkCzPFIyKM7:TR?= M17F[3NCVkeHUh?=
NCI-H64 NHG5ZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X0RWlEPTB;MD6wN|g1OiEQvF2= NUTjeo1XW0GQR1XS
EW-16 M3j3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEO5NFkh|ryP NVK4dnBpW0GQR1XS
CAL-51 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMESwNFUh|ryP Ml7hV2FPT0WU
KYSE-150 M{G3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;WTWM2OD1yLkC0NFEyKM7:TR?= M1;2TnNCVkeHUh?=
SW1710 NF7wPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMESwNVgh|ryP NV3zXFlYW0GQR1XS
HuP-T4 NIiy[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDFNlVKSzVyPUCuNFQyOThizszN MojyV2FPT0WU
LB373-MEL-D MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILJPGNKSzVyPUCuNFQzOzJizszN NILxUJJUSU6JRWK=
EW-13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPBTWM2OD1yLkC0OFA3KM7:TR?= MnzTV2FPT0WU
HT-29 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWwTWM2OD1yLkC0OFkh|ryP NEDaU3NUSU6JRWK=
SCC-25 M2Hqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMES0PVQh|ryP MmKyV2FPT0WU
REH Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvXdIVKSzVyPUCuNFQ3OzVizszN NV[2XpgyW0GQR1XS
L-363 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMES2O|kh|ryP NYi4OY1FW0GQR1XS
NCI-H1770 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMES2PVch|ryP MWDTRW5ITVJ?
CHL-1 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zae2lEPTB;MD6wOFg2PyEQvF2= M3XHenNCVkeHUh?=
ES1 NXnpXYsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMES4PFUh|ryP Ml[4V2FPT0WU
SCC-15 M2j6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT0TWM2OD1yLkC0PVAzKM7:TR?= MXPTRW5ITVJ?
MRK-nu-1 M4LWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmxZ2RZUUN3ME2wMlA1QTN4IN88US=> M120TnNCVkeHUh?=
PF-382 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MleyTWM2OD1yLkC0PVM6KM7:TR?= M3\MNnNCVkeHUh?=
COLO-680N MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;N[mlEPTB;MD6wOVA1PyEQvF2= NV;yPZE6W0GQR1XS
LK-2 NUL6cpV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHKS|k4UUN3ME2wMlA2ODZ|IN88US=> MXPTRW5ITVJ?
NCI-H2342 M12w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELiNGhKSzVyPUCuNFUyOTdizszN Mn\mV2FPT0WU
HMV-II NFyz[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEWyN|kh|ryP MmrwV2FPT0WU
PC-14 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULZNId7UUN3ME2wMlA2OjV{IN88US=> NHPWU4VUSU6JRWK=
COLO-320-HSR NWL0Zm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3UT3ZKSzVyPUCuNFUzQDlizszN NW\4eIk5W0GQR1XS
697 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj4ZoNnUUN3ME2wMlA2OzJ|IN88US=> NHvDXpRUSU6JRWK=
NEC8 NYC4[2FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfsTWM2OD1yLkC1OVkh|ryP NG\iS2pUSU6JRWK=
LCLC-97TM1 NHG4NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm1bFhKSzVyPUCuNFU2QTRizszN MXrTRW5ITVJ?
Daoy Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LHbmlEPTB;MD6wOVYyPiEQvF2= M{Lnc3NCVkeHUh?=
ETK-1 MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7KT3pKSzVyPUCuNFU3PzJizszN NUD5W|hIW0GQR1XS
A388 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjOPG9KSzVyPUCuNFU3QTVizszN NWDtOJQ6W0GQR1XS
COLO-205 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SzNWlEPTB;MD6wOVcyPiEQvF2= MoLSV2FPT0WU
SK-PN-DW NEfveWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[0emlKSzVyPUCuNFU4OjlizszN MWXTRW5ITVJ?
SF268 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7RRpBLUUN3ME2wMlA2PzV4IN88US=> MV7TRW5ITVJ?
OCI-AML2 NYPUR5J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEW3O|ch|ryP M3LoNXNCVkeHUh?=
GAMG MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfhTWM2OD1yLkC1PEDPxE1? Mn7WV2FPT0WU
BCPAP MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMEW4PVIh|ryP M1T1TnNCVkeHUh?=
BC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3yTWM2OD1yLkC2NFIzKM7:TR?= MX3TRW5ITVJ?
IA-LM NGL5V3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETuSZRKSzVyPUCuNFYxPTNizszN M13XW3NCVkeHUh?=
NCI-H1299 NH7QfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDkSGRPUUN3ME2wMlA3OTNizszN Mke2V2FPT0WU
COR-L23 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvkWnBKSzVyPUCuNFYyOzRizszN NWHORmZEW0GQR1XS
KYSE-180 NIewXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwME[xOFIh|ryP M3TJcXNCVkeHUh?=
LOXIMVI MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPX[WZrUUN3ME2wMlA3OTh6IN88US=> MoPwV2FPT0WU
BL-41 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnl[IVKSzVyPUCuNFYzOTlizszN MoHaV2FPT0WU
BL-70 NYD3XHVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwME[zNFIh|ryP NXvLVHBiW0GQR1XS
NOS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7ud5N6UUN3ME2wMlA3PDFzIN88US=> MXrTRW5ITVJ?
NB13 NX23PZBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG1SpREUUN3ME2wMlA3PDJzIN88US=> MkTLV2FPT0WU
CAL-27 NVXKOWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETDZVNKSzVyPUCuNFY1PjRizszN MVPTRW5ITVJ?
CA46 NETkTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH3TWM2OD1yLkC2OVM4KM7:TR?= M3XXZXNCVkeHUh?=
SW962 NYXReVdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD1yLkC2OVY6KM7:TR?= NHexbmpUSU6JRWK=
NCI-H226 NFjUbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwME[2N|Ih|ryP MV7TRW5ITVJ?
KYSE-70 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\QV2lEPTB;MD6wOlk1PSEQvF2= NUWyPXRSW0GQR1XS
Daudi NYjWdok1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLoWW56UUN3ME2wMlA4ODhzIN88US=> MoXiV2FPT0WU
SW626 NV;V[GNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPIU5pTUUN3ME2wMlA4OjB2IN88US=> M{XqXHNCVkeHUh?=
ESS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;EWJNKSzVyPUCuNFczPDZizszN Mkn6V2FPT0WU
YT MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMEezOFUh|ryP NF36OY9USU6JRWK=
P12-ICHIKAWA NGe4XW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjmU3RuUUN3ME2wMlA4OzR7IN88US=> NX;iWIhPW0GQR1XS
BxPC-3 M4TvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\mcWlEPTB;MD6wO|Q2QCEQvF2= NXvlZlNGW0GQR1XS
CTV-1 M{Xnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\zTWM2OD1yLkC3OVE4KM7:TR?= MX3TRW5ITVJ?
MLMA MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC2fmZKSzVyPUCuNFc2OzRizszN M3PNN3NCVkeHUh?=
WSU-NHL M3OyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfyNYhlUUN3ME2wMlA4PTV2IN88US=> NXq3XJl1W0GQR1XS
CTB-1 NIS5e|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TEWWlEPTB;MD6wO|U5QCEQvF2= MnP2V2FPT0WU
MMAC-SF M4Hne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rsWWlEPTB;MD6wO|Y3QCEQvF2= Ml3jV2FPT0WU
8-MG-BA M4nvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3uemlOUUN3ME2wMlA4QDBzIN88US=> NEHjToFUSU6JRWK=
NCI-H358 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\sTWM2OD1yLkC3PFc6KM7:TR?= M4nVbnNCVkeHUh?=
BFTC-905 NU\EdI1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TldGlEPTB;MD6wO|kxQSEQvF2= M2TvNnNCVkeHUh?=
NCI-H727 M2Kwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3IcldvUUN3ME2wMlA5ODV|IN88US=> NHXkfVFUSU6JRWK=
CHP-212 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHkdlhKSzVyPUCuNFgxQTVizszN NYqweJNuW0GQR1XS
HOP-62 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEiyOFUh|ryP M1zkU3NCVkeHUh?=
CESS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v5XWlEPTB;MD6wPFI3QSEQvF2= MoXEV2FPT0WU
HuCCT1 NFnG[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLxOHhKSzVyPUCuNFg{OzNizszN MV\TRW5ITVJ?
DEL M3PGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEizOFch|ryP NXvYfVNTW0GQR1XS
5637 NH7xWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS1[FNKSzVyPUCuNFg{PjdizszN NFzDbFZUSU6JRWK=
RS4-11 M1z6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nTemlEPTB;MD6wPFQ6PyEQvF2= NV;ZZmhMW0GQR1XS
KURAMOCHI Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTRdlljUUN3ME2wMlA5PTB7IN88US=> MV3TRW5ITVJ?
A427 NETBXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfnWZRUUUN3ME2wMlA5PTF{IN88US=> M4TRSnNCVkeHUh?=
A3-KAW MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfIV3pqUUN3ME2wMlA5PTZ4IN88US=> MWnTRW5ITVJ?
LS-123 NW[5b3NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XXVmlEPTB;MD6wPFcyQSEQvF2= M2n6cnNCVkeHUh?=
LoVo NEH6VWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPHTWM2OD1yLkC4O|Ih|ryP MWjTRW5ITVJ?
PA-1 NI\vWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq3[phKSzVyPUCuNFg4PjlizszN NWCxcVFrW0GQR1XS
CP50-MEL-B MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fXTWlEPTB;MD6wPFc6OyEQvF2= M2iwUHNCVkeHUh?=
A431 NXLuR3hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X5bmlEPTB;MD6wPFgxOSEQvF2= NYDoSo5rW0GQR1XS
HCT-116 NU\nO3V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz3TWM2OD1yLkC4PFAzKM7:TR?= MkXHV2FPT0WU
A4-Fuk NXe0SIN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEi5OFch|ryP MWrTRW5ITVJ?
RPMI-6666 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\2TWM2OD1yLkC4PVY4KM7:TR?= MmDBV2FPT0WU
Calu-6 NITjcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7BZXVRUUN3ME2wMlA6ODJ7IN88US=> MWDTRW5ITVJ?
KMOE-2 NGDtUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D6cGlEPTB;MD6wPVA{QSEQvF2= M{PwbnNCVkeHUh?=
A704 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm2RYRKSzVyPUCuNFkyPSEQvF2= M1T2ZnNCVkeHUh?=
HO-1-N-1 NUPCSFNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEmyOFkh|ryP NH3VcVZUSU6JRWK=
NCI-H2122 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK0TWM2OD1yLkC5N|c5KM7:TR?= MUXTRW5ITVJ?
U-698-M M{PacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHCS|FKSzVyPUCuNFk1ODlizszN M2\zS3NCVkeHUh?=
IST-SL2 M1TDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEm0Olgh|ryP M4Xse3NCVkeHUh?=
TE-10 NHHUT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEm1PFQh|ryP M{nafHNCVkeHUh?=
PANC-03-27 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPLTWM2OD1yLkC5OlcyKM7:TR?= MXfTRW5ITVJ?
KYSE-410 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEm3PVch|ryP MoXvV2FPT0WU
TE-8 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;NTWM2OD1yLkC5PFg2KM7:TR?= MXrTRW5ITVJ?
MN-60 M{jUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr6TWM2OD1yLkC5PFk4KM7:TR?= MYfTRW5ITVJ?
NCI-H460 M3TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnIelNNUUN3ME2wMlExODlizszN MYDTRW5ITVJ?
LB771-HNC NXfVZ21ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\GPGlEPTB;MD6xNFI2PSEQvF2= NYLCTWZFW0GQR1XS
ES4 M3TWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjnNZRKSzVyPUCuNVAzPjRizszN M1\OdHNCVkeHUh?=
HUTU-80 NHHQN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPVTWM2OD1yLkGwN|Y2KM7:TR?= M33zUHNCVkeHUh?=
647-V MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3p[YZ5UUN3ME2wMlExPDB6IN88US=> MWjTRW5ITVJ?
HTC-C3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDsfYxyUUN3ME2wMlExPDN{IN88US=> NV3TR4YzW0GQR1XS
NTERA-S-cl-D1 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDwOVJ1UUN3ME2wMlExPDR6IN88US=> MYXTRW5ITVJ?
A2058 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7xTWM2OD1yLkGwOlU2KM7:TR?= MlPhV2FPT0WU
MZ1-PC M2e3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjlTWM2OD1yLkGwPFMh|ryP NEjHcYlUSU6JRWK=
J82 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO1[oJnUUN3ME2wMlExQDh2IN88US=> NFnMWGNUSU6JRWK=
ARH-77 NUHUbI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HHWWlEPTB;MD6xNUDPxE1? M3rxWnNCVkeHUh?=
Ca9-22 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHaTnFKUUN3ME2wMlEyOTJ6IN88US=> MlnyV2FPT0WU
NCI-H1648 NF[wSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESxV4RKSzVyPUCuNVEzQDZizszN NE[yd5pUSU6JRWK=
MC116 NUD6PXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X5dWlEPTB;MD6xNVM{PyEQvF2= M2DLS3NCVkeHUh?=
EoL-1-cell M4nzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnYZnZGUUN3ME2wMlEyPDZ5IN88US=> NHXxUpNUSU6JRWK=
PANC-10-05 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVniW5ZuUUN3ME2wMlEyPDlzIN88US=> M2\xcXNCVkeHUh?=
SF539 M4T1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37qZmlEPTB;MD6xNVYyPiEQvF2= MWXTRW5ITVJ?
ES8 Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf6NlRFUUN3ME2wMlEyPjN|IN88US=> MX7TRW5ITVJ?
NCI-H810 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL1dVFyUUN3ME2wMlEyPjZ2IN88US=> MorEV2FPT0WU
J-RT3-T3-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\4[FlWUUN3ME2wMlEyPzVizszN NInGWWdUSU6JRWK=
NY NXP1SFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMUG4NVch|ryP MmnmV2FPT0WU
NCI-SNU-1 NGCxXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMUKxOFgh|ryP MXfTRW5ITVJ?
EFM-19 NEHLTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq3TWM2OD1yLkGyN|c1KM7:TR?= MUnTRW5ITVJ?
HCC1806 M{f3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTpcVNUUUN3ME2wMlEzOzh|IN88US=> MYDTRW5ITVJ?
HCE-T MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMUK1N|Eh|ryP NHPzS2VUSU6JRWK=
HT-1376 M2nwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfrTWM2OD1yLkGyOlY5KM7:TR?= NWX3dm91W0GQR1XS
BE-13 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvWTWM2OD1yLkGyPFY3KM7:TR?= NGPhSnBUSU6JRWK=
NCI-H520 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLwTWM2OD1yLkGyPFY4KM7:TR?= M3vyTnNCVkeHUh?=
SK-MES-1 M4TmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLtOXVKSzVyPUCuNVI6OTNizszN NWjuS3F2W0GQR1XS
SNU-423 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMUK5NVQh|ryP MX\TRW5ITVJ?
Ramos-2G6-4C10 M1X2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrRTWM2OD1yLkGyPVE3KM7:TR?= MUnTRW5ITVJ?
EW-18 M{LiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXKZXVMUUN3ME2wMlE{ODJ4IN88US=> M3LWZnNCVkeHUh?=
NCI-H2087 MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDkelRuUUN3ME2wMlE{ODJ5IN88US=> NU\2coN1W0GQR1XS
COLO-792 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rKPGlEPTB;MD6xN|E3PSEQvF2= MonpV2FPT0WU
QIMR-WIL MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PIeWlEPTB;MD6xN|IzOyEQvF2= MWDTRW5ITVJ?
ACHN NHT3fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTLVIpKSzVyPUCuNVMzPDdizszN M1e5ZXNCVkeHUh?=
RPMI-8866 NFTOelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPt[4dKSzVyPUCuNVMzPjFizszN M{DOXXNCVkeHUh?=
SK-LU-1 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\qUGlEPTB;MD6xN|Q1QSEQvF2= Mn\kV2FPT0WU
SK-UT-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUO2Nlgh|ryP MVPTRW5ITVJ?
MFE-296 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13mfmlEPTB;MD6xN|g3PCEQvF2= MXnTRW5ITVJ?
RD NFjrbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrhWndKSzVyPUCuNVM6QTdizszN NV7xdHhpW0GQR1XS
LS-411N MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHGTHNqUUN3ME2wMlE1Ojl3IN88US=> MmDVV2FPT0WU
NCI-H747 NVrScJcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HnTWlEPTB;MD6xOFMh|ryP MoTNV2FPT0WU
ES6 M2\XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnSTWM2OD1yLkG0N|Yh|ryP MkTsV2FPT0WU
TE-1 NYjY[3F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rDfmlEPTB;MD6xOFQxPyEQvF2= M3Tt[XNCVkeHUh?=
SJSA-1 NFuxR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMUS3NFch|ryP MVrTRW5ITVJ?
NCI-H1355 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMUWyPVMh|ryP NG\YT4JUSU6JRWK=
HEL NHmxeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDVeZRKSzVyPUCuNVU1PDdizszN MVTTRW5ITVJ?
639-V MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\CT2lEPTB;MD6xOVU6PiEQvF2= NYHHfopGW0GQR1XS
AN3-CA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfoPZo{UUN3ME2wMlE2PjN7IN88US=> M1jrbXNCVkeHUh?=
SK-MEL-2 M4fzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HyTmlEPTB;MD6xOVY3QCEQvF2= NHzETmlUSU6JRWK=
SW872 NWraWow1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jncmlEPTB;MD6xOlA1OiEQvF2= NIrxVWdUSU6JRWK=
DU-4475 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMU[xOlIh|ryP NWDpOZBMW0GQR1XS
YKG-1 NUDuOWdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPxTWM2OD1yLkG2Nlc{KM7:TR?= NHPnXWZUSU6JRWK=
GT3TKB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rM[WlEPTB;MD6xOlI5OyEQvF2= NGDi[3NUSU6JRWK=
GB-1 M{\uZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMU[0NlQh|ryP MnG5V2FPT0WU
KARPAS-422 NVHnR40{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TaPGlEPTB;MD6xOlU4PCEQvF2= Mnn4V2FPT0WU
ATN-1 M2rTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMU[2OVYh|ryP NIHBdJlUSU6JRWK=
HLE MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMU[4O|ch|ryP NUfw[ZVGW0GQR1XS
D-542MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfPe5hKSzVyPUCuNVY6QDZizszN M3XvS3NCVkeHUh?=
EB-3 NWP5UmRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX0TWM2OD1yLkG3N|Eh|ryP M1jocXNCVkeHUh?=
HCC1143 NEjqOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm4ZXVKSzVyPUCuNVc{QTZizszN NWLUPZo2W0GQR1XS
DJM-1 NXLYNWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMUe0OVEh|ryP MUXTRW5ITVJ?
BT-474 NH3MXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUe0PFkh|ryP MY\TRW5ITVJ?
BB65-RCC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PXO2lEPTB;MD6xO|U1PSEQvF2= M4q5SnNCVkeHUh?=
NCI-H292 NEPCPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMUe2NFEh|ryP NFz0dGJUSU6JRWK=
MKN28 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMUe2OVMh|ryP MlHOV2FPT0WU
TK10 NUfkcmlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMUe3NFIh|ryP M172PHNCVkeHUh?=
TYK-nu MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnPc|NKSzVyPUCuNVc6PDlizszN NGLiUZBUSU6JRWK=
8305C NHzV[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMUe5O|Eh|ryP M1v0SHNCVkeHUh?=
MV-4-11 M1f2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMUe5O|ch|ryP NWPMOoZlW0GQR1XS
NCI-H522 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMUiwPVQh|ryP NH;m[GZUSU6JRWK=
Hs-578-T NHzMOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzMd3JxUUN3ME2wMlE5Ojl{IN88US=> Mk\VV2FPT0WU
LCLC-103H M3fTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3LUm1KSzVyPUCuNVg2OjdizszN NHvtV21USU6JRWK=
MHH-ES-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[yTWM2OD1yLkG4OlI6KM7:TR?= M2TWd3NCVkeHUh?=
NCI-H441 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\qflhRUUN3ME2wMlE6OTR6IN88US=> M2\kV3NCVkeHUh?=
AM-38 NI\4OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnPW|VKSzVyPUCuNVkzOjVizszN NXvN[HdLW0GQR1XS
SW1783 NIfYdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jpPGlEPTB;MD6xPVMxPSEQvF2= NWDvfHNxW0GQR1XS
SK-HEP-1 M3zENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq4TWM2OD1yLkG5OlM4KM7:TR?= M4fU[XNCVkeHUh?=
OAW-28 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HGWGlEPTB;MD6yNFE4QCEQvF2= MmXOV2FPT0WU
TE-15 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMkCyOVIh|ryP NV\RXIlQW0GQR1XS
HCE-4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ieHBKSzVyPUCuNlAzQDRizszN MlXmV2FPT0WU
JiyoyeP-2003 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT4TWM2OD1yLkKwN|M3KM7:TR?= NIDBbpdUSU6JRWK=
OVCAR-4 NEDxfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMkC2Nlgh|ryP MXfTRW5ITVJ?
SNU-449 NIjmRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:y[WlEPTB;MD6yNFc6PyEQvF2= NIXqWmFUSU6JRWK=
SBC-5 NW\HSYlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkGyNVUh|ryP M17reXNCVkeHUh?=
T84 NX3vcnJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXBTWM2OD1yLkKxNlQ5KM7:TR?= M{XrVnNCVkeHUh?=
LP-1 M2XyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTnTWM2OD1yLkKxN|AzKM7:TR?= MYXTRW5ITVJ?
MG-63 NVixeHNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X2UWlEPTB;MD6yNVM5OiEQvF2= Mmr2V2FPT0WU
OAW-42 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Sx[2lEPTB;MD6yNVQ4QCEQvF2= Ml7LV2FPT0WU
L-540 NYTpRotxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XQNWlEPTB;MD6yNVU6QCEQvF2= NUjzOmE4W0GQR1XS
RH-1 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMkKyOFIh|ryP NFGyTGZUSU6JRWK=
HCT-15 NUnDV5poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXSfoFKSzVyPUCuNlI1QDRizszN M3zlW3NCVkeHUh?=
OCUB-M M1\wWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMkK0PFgh|ryP MlL2V2FPT0WU
GP5d MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXGTWM2OD1yLkKyOVI5KM7:TR?= M3S0cHNCVkeHUh?=
NCI-H2030 NETEZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPlXXdtUUN3ME2wMlIzPzN2IN88US=> NX\IXlRwW0GQR1XS
ML-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O2T2lEPTB;MD6yNlg5QSEQvF2= NGfrWZdUSU6JRWK=
CAL-39 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMkK5N|Yh|ryP MXLTRW5ITVJ?
MIA-PaCa-2 M3:5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m5cWlEPTB;MD6yN|I5PyEQvF2= NXP2PVh7W0GQR1XS
TE-9 M1PrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXMOnFKSzVyPUCuNlM{OiEQvF2= M3TMcXNCVkeHUh?=
LB2518-MEL MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jmTWlEPTB;MD6yN|M4OiEQvF2= NWjMVGdnW0GQR1XS
DB NH;Be5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMkO0N|gh|ryP Mk\CV2FPT0WU
NCI-H596 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnLWGRKSzVyPUCuNlM2PzFizszN MWnTRW5ITVJ?
SW1990 NE\kU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMkO5OFYh|ryP M2fTSnNCVkeHUh?=
P30-OHK M{fFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Twc2lEPTB;MD6yOFA2KM7:TR?= M{POWnNCVkeHUh?=
ALL-PO M1i4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMkSxOlkh|ryP NILm[YpUSU6JRWK=
Saos-2 NW\HbnFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO0PGdKSzVyPUCuNlQ2PzFizszN NV7yeZlwW0GQR1XS
MFH-ino MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMkS2PVIh|ryP MmLZV2FPT0WU
OE33 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fjSGlEPTB;MD6yOVEyKM7:TR?= Mle2V2FPT0WU
Calu-3 NY\2bZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\tTWM2OD1yLkK1Nlk4KM7:TR?= NUDLN|V[W0GQR1XS
HT NHjKNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMkW2NlEh|ryP MWHTRW5ITVJ?
LXF-289 NUP6SoZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfqTWM2OD1yLkK1PVg1KM7:TR?= M17kcHNCVkeHUh?=
KGN NES1TYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMk[wPFkh|ryP NGPFXWlUSU6JRWK=
NCI-H1417 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnpTWM2OD1yLkK2OVI1KM7:TR?= NYnle3ZQW0GQR1XS
SF126 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDienNKSzVyPUCuNlc{ODJizszN M1T4XXNCVkeHUh?=
SAS M{HaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[3TWM2OD1yLkK3N|A5KM7:TR?= M{fwWnNCVkeHUh?=
22RV1 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PrZmlEPTB;MD6yO|M4QCEQvF2= NE\aXG9USU6JRWK=
GI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvJVFRZUUN3ME2wMlI4PDh5IN88US=> NG\RRW9USU6JRWK=
ES3 NYnrcINKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r3W2lEPTB;MD6yO|c3OyEQvF2= MX7TRW5ITVJ?
NB1 NGr5b5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M121XGlEPTB;MD6yO|g4PiEQvF2= MoLVV2FPT0WU
NCI-H650 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC3cJlKSzVyPUCuNlg{ODJizszN MVzTRW5ITVJ?
IST-MES1 NF;5PFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrmTWM2OD1yLkK4OVU1KM7:TR?= NHzV[|BUSU6JRWK=
UM-UC-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmyVZVKSzVyPUCuNlkyPCEQvF2= NFixbWtUSU6JRWK=
CAL-120 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMkm2N|Eh|ryP M3XwRXNCVkeHUh?=
UACC-62 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP5dXNKSzVyPUCuN|AzPDFizszN MlPhV2FPT0WU
TE-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwM{CyOFkh|ryP MXfTRW5ITVJ?
MKN1 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwM{CzOkDPxE1? M{Lnd3NCVkeHUh?=
KS-1 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwM{C1NlYh|ryP NVnxeJZHW0GQR1XS
GCIY MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi0fIE2UUN3ME2wMlMyODB{IN88US=> Mo\mV2FPT0WU
OVCAR-5 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwM{GxNFYh|ryP M2LsR3NCVkeHUh?=
U-266 NG[3cGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwM{GxOFch|ryP NFzYSHJUSU6JRWK=
Calu-1 M4Pye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf1PZhuUUN3ME2wMlMyOjh7IN88US=> M3rGd3NCVkeHUh?=
SK-LMS-1 NHXqe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zaUmlEPTB;MD6zNVQzQSEQvF2= MW\TRW5ITVJ?
COLO-741 NGHKNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfxTWZKSzVyPUCuN|E3OTRizszN M2flR3NCVkeHUh?=
RPMI-8226 M320cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC4WYpKSzVyPUCuN|E3PDFizszN MXLTRW5ITVJ?
KM12 NFXtUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjmbIR1UUN3ME2wMlMyQDNizszN MmXWV2FPT0WU
NMC-G1 M{L4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofWTWM2OD1yLkOxPFYh|ryP MkLCV2FPT0WU
SJRH30 M3\hTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrFTWM2OD1yLkOyNFUzKM7:TR?= NYW4NnFPW0GQR1XS
COR-L105 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny1TWM2OD1yLkOyNlE5KM7:TR?= NUDUR2FJW0GQR1XS
IM-9 NXj4T4RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;IXno1UUN3ME2wMlM{ODJzIN88US=> MXHTRW5ITVJ?
TE-12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLreoNKSzVyPUCuN|M{OTdizszN NFHofXFUSU6JRWK=
KG-1 NEPJcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwM{O0N|Ih|ryP MVzTRW5ITVJ?
U251 NX\BNXpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M163OmlEPTB;MD6zN|Q2PiEQvF2= MVHTRW5ITVJ?
EFO-27 MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\yfolKUUN3ME2wMlM{QTVzIN88US=> MVHTRW5ITVJ?
EW-24 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLOTWM2OD1yLkOzPVg1KM7:TR?= MYfTRW5ITVJ?
SF295 NIj5VJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjZeGVpUUN3ME2wMlM{QTl7IN88US=> MYTTRW5ITVJ?
MC-IXC MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS5eJVKSzVyPUCuN|Q2KM7:TR?= NGS3SZBUSU6JRWK=
NCI-H2405 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonpTWM2OD1yLkO0O|MzKM7:TR?= NHzKTGlUSU6JRWK=
NCI-H2009 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknyTWM2OD1yLkO0O|M6KM7:TR?= NFr4UoNUSU6JRWK=
LB1047-RCC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7JTWM2OD1yLkO1PFE2KM7:TR?= NH3lVJpUSU6JRWK=
KNS-81-FD MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnhemZKSzVyPUCuN|Y3PjdizszN NULYenJNW0GQR1XS
HOP-92 NEPpdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;yTWM2OD1yLkO2PFMh|ryP NF74UYhUSU6JRWK=
L-428 NVrkPW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPsR4FiUUN3ME2wMlM4ODF4IN88US=> NF\FWYNUSU6JRWK=
C3A NYLwRmNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwM{ezO|kh|ryP NGjhSHBUSU6JRWK=
NCI-H1792 NVnQU25ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwM{e2OVUh|ryP M3jKWHNCVkeHUh?=
HuH-7 M4DmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrHUIhKSzVyPUCuN|c6OSEQvF2= MoDsV2FPT0WU
AGS M2LpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnLWlhQUUN3ME2wMlM5PjN6IN88US=> NHqyVZhUSU6JRWK=
HT-1197 M1TQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW2TWM2OD1yLkO5OFYh|ryP NWOyV4tMW0GQR1XS
CGTH-W-1 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LaXWlEPTB;MD6zPVkyOyEQvF2= M1fkcnNCVkeHUh?=
KNS-42 NVnLUldST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHMWXA4UUN3ME2wMlQxODR3IN88US=> NEm0eIhUSU6JRWK=
HuO-3N1 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO1TWM2OD1yLkSwNFU2KM7:TR?= MkjHV2FPT0WU
VMRC-RCZ M2jGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12z[2lEPTB;MD60NFMxOyEQvF2= NEHrUo5USU6JRWK=
SW954 NGDudY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHST4ZKSzVyPUCuOFA{OzVizszN M3n6c3NCVkeHUh?=
MES-SA MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOzRlNKSzVyPUCuOFA2ODVizszN MkTqV2FPT0WU
Ca-Ski NHXvSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf3[G5KSzVyPUCuOFA2OjRizszN NUHYWJh6W0GQR1XS
SW13 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwNEC2NlYh|ryP NXTBRnRiW0GQR1XS
NCI-H1437 M4rlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW1XXBKSzVyPUCuOFA5ODVizszN MWLTRW5ITVJ?
U-118-MG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTNcnhrUUN3ME2wMlQxQTB2IN88US=> NEfTPVlUSU6JRWK=
NCI-H1734 NXq5eItHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT0dG5KSzVyPUCuOFIxOTNizszN MmXLV2FPT0WU
HDLM-2 NF7NVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwNEKwN|Mh|ryP Mo[1V2FPT0WU
AU565 NXjHcoV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwNEK0Olgh|ryP MlvMV2FPT0WU
FADU MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XEcGlEPTB;MD60NlY1QSEQvF2= MX\TRW5ITVJ?
OS-RC-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLzNnhMUUN3ME2wMlQ{ODh|IN88US=> MVHTRW5ITVJ?
CAMA-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnndpJKSzVyPUCuOFM3OjZizszN MXPTRW5ITVJ?
MONO-MAC-6 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXSUW9KSzVyPUCuOFM5PDlizszN NYjqRWE4W0GQR1XS
LB831-BLC MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO4R3FFUUN3ME2wMlQ1OzdzIN88US=> MofwV2FPT0WU
SW982 NGnNbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfPV5pKSzVyPUCuOFQ2OjhizszN MkHuV2FPT0WU
SCC-3 NITodVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvRTWM2OD1yLkS0OVc6KM7:TR?= MoPZV2FPT0WU
C32 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPyTWM2OD1yLkS1NlI6KM7:TR?= NUL2eYRKW0GQR1XS
BFTC-909 NGPQbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnnd5pFUUN3ME2wMlQ2Ojl7IN88US=> M1nz[XNCVkeHUh?=
MEG-01 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL5TWM2OD1yLkS1N|c{KM7:TR?= Mk\GV2FPT0WU
M14 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33EfmlEPTB;MD60OVk4QSEQvF2= NWXrfI5iW0GQR1XS
MPP-89 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\KTWM2OD1yLkS2NlU3KM7:TR?= M4\qNHNCVkeHUh?=
HCC1937 M{fLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPrTWM2OD1yLkS2N|g1KM7:TR?= M4D1cXNCVkeHUh?=
SW837 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDPe3RKSzVyPUCuOFY4OjJizszN MVjTRW5ITVJ?
DU-145 NGDpOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;RSmlEPTB;MD60OlczQSEQvF2= M2\wS3NCVkeHUh?=
LB996-RCC NUPLTItIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDsfJZCUUN3ME2wMlQ4ODV2IN88US=> MVzTRW5ITVJ?
C8166 NWnXb5gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfUSVhoUUN3ME2wMlQ4PCEQvF2= MYjTRW5ITVJ?
MOLT-4 MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHzNmNKSzVyPUCuOFc4OzRizszN NXv0VGNwW0GQR1XS
DMS-53 NW\kZmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnRcoRmUUN3ME2wMlQ4QDB7IN88US=> NUDpNploW0GQR1XS
TE-5 NIraN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnte|FKSzVyPUCuOFg{ODVizszN MYHTRW5ITVJ?
KYSE-520 NYPXXXBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zSbWlEPTB;MD60PFM1OyEQvF2= M4DzVHNCVkeHUh?=
Detroit562 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r6OGlEPTB;MD60PFg3KM7:TR?= NFzkXndUSU6JRWK=
SIMA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTPTWM2OD1yLkS5OFE4KM7:TR?= NEnsSHJUSU6JRWK=
NCI-H1651 NU\DPZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3uTWM2OD1yLkS5Olch|ryP Mn\qV2FPT0WU
HCC1599 NF7YPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuzOopKSzVyPUCuOFk6PTVizszN M{HVe3NCVkeHUh?=
ABC-1 NUHVR|hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnLTWM2OD1yLkWwOFk3KM7:TR?= NF;vc4pUSU6JRWK=
CAL-33 M2fXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwNUC4OFQh|ryP NFLlRnZUSU6JRWK=
OPM-2 NVntfXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNUC5N|ch|ryP M4\KNHNCVkeHUh?=
RPMI-7951 NWTLbYVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTrcWJKSzVyPUCuOVA6PTdizszN NH;iVnZUSU6JRWK=
HT-1080 NXTmNYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnWZo9VUUN3ME2wMlUyOTF7IN88US=> NVrZXWZjW0GQR1XS
LC4-1 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\mXVFKSzVyPUCuOVE1ODNizszN Ml;zV2FPT0WU
OVCAR-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fyO2lEPTB;MD61NVU4KM7:TR?= M17ySXNCVkeHUh?=
CAPAN-1 M16zcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\UNI9KSzVyPUCuOVIzQDhizszN NGW4U4JUSU6JRWK=
SK-OV-3 M4LHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PEXmlEPTB;MD61NlQ{PCEQvF2= NF\yO5VUSU6JRWK=
HuP-T3 NFL2W3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwNUK4Nlch|ryP MXPTRW5ITVJ?
NCI-H838 NH7KfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvQTWM2OD1yLkWyPFQ6KM7:TR?= M3Xv[nNCVkeHUh?=
K5 NWLDT2l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPmcm01UUN3ME2wMlU{OjBzIN88US=> M{DK[nNCVkeHUh?=
CAL-72 M2rVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXZO4V5UUN3ME2wMlU{Ozh5IN88US=> MXnTRW5ITVJ?
NH-12 M3XXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L0dWlEPTB;MD61N|k2QSEQvF2= NIDmbI1USU6JRWK=
SNB75 NETIU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILhNnZKSzVyPUCuOVU4OyEQvF2= NU\sUIxHW0GQR1XS
BPH-1 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLRXXdKSzVyPUCuOVY{PDRizszN MnjmV2FPT0WU
NOMO-1 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TiW2lEPTB;MD61OlM4OiEQvF2= M4XGNHNCVkeHUh?=
G-402 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwNU[0PVkh|ryP M1PXeXNCVkeHUh?=
NCI-H2052 NHKyN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwNU[3OFEh|ryP NXn0VFhsW0GQR1XS
RCM-1 NEnrWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfOTWM2OD1yLkW3NVY3KM7:TR?= MWHTRW5ITVJ?
COR-L279 M3HsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwNUexPFUh|ryP NFv0dWZUSU6JRWK=
A253 M4f5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLER|FKSzVyPUCuOVc2OjVizszN NH6wW4FUSU6JRWK=
SK-MM-2 M3naeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX4O5J6UUN3ME2wMlU4Pjd7IN88US=> MlH1V2FPT0WU
NCI-H1703 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TsUmlEPTB;MD61PVQzPyEQvF2= NVvHNJBsW0GQR1XS
UACC-257 NITZb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPDfFI5UUN3ME2wMlU6PDh5IN88US=> NHjrVXBUSU6JRWK=
KALS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37MeWlEPTB;MD62NFAyOSEQvF2= M1fiO3NCVkeHUh?=
ES5 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLZO2JKSzVyPUCuOlA1QCEQvF2= NH61d25USU6JRWK=
MHH-CALL-2 M3XzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDsWVhKSzVyPUCuOlA5QDhizszN MknQV2FPT0WU
ChaGo-K-1 NGDrTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjtfZdKSzVyPUCuOlEzOjlizszN MXXTRW5ITVJ?
TGBC1TKB M1vERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNkG5PEDPxE1? MVHTRW5ITVJ?
KU-19-19 NHfoeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHVdmVKSzVyPUCuOlQ2QDZizszN MkHZV2FPT0WU
COLO-684 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Hw[mlEPTB;MD62OVYyOSEQvF2= MmnwV2FPT0WU
LS-1034 M{nnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwNkW4NVkh|ryP MUXTRW5ITVJ?
RT-112 M3\qT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf6XndKSzVyPUCuOlY2QDdizszN Mo\XV2FPT0WU
Capan-2 M2rsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTLTWM2OD1yLk[2OlIzKM7:TR?= NYTYeYpjW0GQR1XS
HSC-4 M4ricGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwNk[2PVgh|ryP M{K1dXNCVkeHUh?=
COLO-824 M3zUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\wR3VKSzVyPUCuOlc5OjNizszN M{nIZXNCVkeHUh?=
NCI-H2170 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLQVG5pUUN3ME2wMlY5OjV6IN88US=> NUjz[Yw4W0GQR1XS
GDM-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37tTWlEPTB;MD62PFQ6PCEQvF2= NIfOWphUSU6JRWK=
KP-4 M3nRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrJTWM2OD1yLk[5OVc{KM7:TR?= MlPFV2FPT0WU
VA-ES-BJ M3\UW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7KTWM2OD1yLk[5PVg3KM7:TR?= MYDTRW5ITVJ?
KM-H2 MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPaZZhoUUN3ME2wMlcxODlzIN88US=> M3XpWnNCVkeHUh?=
HH M3T3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P1UWlEPTB;MD63NFY3OiEQvF2= MofZV2FPT0WU
DK-MG M2LiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XRNWlEPTB;MD63NVAyPiEQvF2= MXrTRW5ITVJ?
VM-CUB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULEVoxIUUN3ME2wMlcyOjV7IN88US=> MkXWV2FPT0WU
COLO-829 NHLQTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwN{G5PFUh|ryP NEn3emtUSU6JRWK=
OMC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH0[3hKSzVyPUCuO|IyODRizszN NF:2UYNUSU6JRWK=
NB12 M1ruXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vOT2lEPTB;MD63NlUxPCEQvF2= MULTRW5ITVJ?
NCI-H28 M4XPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXTWM2OD1yLke0NFg{KM7:TR?= MYnTRW5ITVJ?
A673 M1\Cdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnIVlg2UUN3ME2wMlc2OTd5IN88US=> NEL3e2dUSU6JRWK=
LB2241-RCC M{H5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwN{[wPFch|ryP NYLuW5dHW0GQR1XS
CCRF-CEM MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwN{ewOVIh|ryP NFHtcHBUSU6JRWK=
NCI-H510A MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7ISpo3UUN3ME2wMlc4OTh4IN88US=> M375NnNCVkeHUh?=
SW48 NUjUNYlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTyTWM2OD1yLke3N|M{KM7:TR?= MmnrV2FPT0WU
NCI-H2081 M4T4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPtTWM2OD1yLke4NVQ4KM7:TR?= NVzMd|hRW0GQR1XS
RMG-I M4Pj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrIN4JKSzVyPUCuO|gzOTJizszN MnjJV2FPT0WU
LU-99A MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwN{i0NVMh|ryP MYXTRW5ITVJ?
KP-N-YS M4H6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17Xe2lEPTB;MD63PFkzOSEQvF2= NGnOPHhUSU6JRWK=
MDA-MB-231 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz5TWM2OD1yLkiwNVMyKM7:TR?= Moi3V2FPT0WU
U031 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LheGlEPTB;MD64NVQzOyEQvF2= MVzTRW5ITVJ?
EVSA-T MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwOEG2O|Ih|ryP NWjwemozW0GQR1XS
MDA-MB-157 NYTTZXBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nrfGlEPTB;MD64NlI4OSEQvF2= Mm\SV2FPT0WU
EHEB NGTlWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjIcFllUUN3ME2wMlgzOjd4IN88US=> NFjwb5JUSU6JRWK=
KINGS-1 NFT1UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHSUnZKSzVyPUCuPFI2PTVizszN M4TDVXNCVkeHUh?=
23132-87 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPqbIhsUUN3ME2wMlgzQDR|IN88US=> NUDObFRUW0GQR1XS
EFO-21 M1HjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX3eXNKSzVyPUCuPFQxQDlizszN NG\2UndUSU6JRWK=
DOK NFK1W|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvQTWM2OD1yLki0PEDPxE1? M3L4eHNCVkeHUh?=
NCI-H2171 NFiwclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwOES5OkDPxE1? MUPTRW5ITVJ?
NCI-SNU-5 M3ixTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;QdWlEPTB;MD64OVU4KM7:TR?= M335NnNCVkeHUh?=
SK-N-DZ NInue|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1voOGlEPTB;MD64OVk1OyEQvF2= MVfTRW5ITVJ?
SNU-C2B M3rRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLjSXB[UUN3ME2wMlg3QDBzIN88US=> NEnmZndUSU6JRWK=
CP66-MEL MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrSTWM2OD1yLki3NVEh|ryP NFfRWYJUSU6JRWK=
SN12C MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nGfmlEPTB;MD64PFY{PyEQvF2= NHzZXWlUSU6JRWK=
A172 M3\yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH4bphtUUN3ME2wMlg5Pjl6IN88US=> NFXIdGtUSU6JRWK=
NCI-H2347 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfLOYxKSzVyPUCuPFg4PTNizszN MnXSV2FPT0WU
NCI-H2228 M4nyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLJPIhKSzVyPUCuPFk{OzlizszN MnThV2FPT0WU
SNU-387 M1vY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwOUCyOlQh|ryP MkTFV2FPT0WU
SK-MEL-24 NGKzNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwOUGzOFQh|ryP NFnwV|dUSU6JRWK=
MDA-MB-468 NVHv[5RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD1yLkmxO|Mh|ryP MVXTRW5ITVJ?
NCI-H1694 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwOUG4O|Yh|ryP MmnIV2FPT0WU
CCF-STTG1 NEDub2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmxV4k6UUN3ME2wMlkzPjN5IN88US=> NHTXUHdUSU6JRWK=
K052 NYXLd2tuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\mc3VKSzVyPUCuPVQxPDdizszN MXXTRW5ITVJ?
NCI-H446 NHfJ[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[2TWM2OD1yLkm1NFEh|ryP MXnTRW5ITVJ?
MFE-280 NFfrboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3uOXdRUUN3ME2wMlk3OjlzIN88US=> NH;hcnVUSU6JRWK=
KU812 MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwOUmzPFkh|ryP NWTGU25bW0GQR1XS
MDA-MB-361 NF\OfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fkXGlEPTB;MD65PVc4PyEQvF2= NFfZdo5USU6JRWK=
Raji NYrnUZNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:yTWM2OD1zLkCyNlY4KM7:TR?= NV;rdnhIW0GQR1XS
TE-6 NXrQdGo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXCTWM2OD1zLkCzOVY3KM7:TR?= M{XO[3NCVkeHUh?=
CAL-148 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPO[Y91UUN3ME2xMlA1PDR|IN88US=> NUi0RVBmW0GQR1XS
NCI-H1963 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PldmlEPTB;MT6wOFU2OyEQvF2= NX\sZ4pvW0GQR1XS
SK-N-AS NIXDT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrZUJRKSzVyPUGuNFQ3QDVizszN M4m4bnNCVkeHUh?=
RERF-LC-MS NXPS[IdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\4U49wUUN3ME2xMlA3OzR7IN88US=> M1j5PXNCVkeHUh?=
BEN NE\vWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\3TnFKSzVyPUGuNFcyOzdizszN M{HTfHNCVkeHUh?=
CAS-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG4TWM2OD1zLkC5NVI{KM7:TR?= NIfPTXpUSU6JRWK=
SW780 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH3SVVKSzVyPUGuNFkyQDFizszN NX3rXXI1W0GQR1XS
LU-65 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzS[IRKSzVyPUGuNFk1OSEQvF2= M3;Z[nNCVkeHUh?=
D-283MED NHjpVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXsTWM2OD1zLkGyNlczKM7:TR?= MlO4V2FPT0WU
HCC2157 NULQfYVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\6XnliUUN3ME2xMlE{PjR{IN88US=> NG\IPGFUSU6JRWK=
RCC10RGB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTmd2NxUUN3ME2xMlE1ODB4IN88US=> Ml[0V2FPT0WU
PLC-PRF-5 M4nh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjVNFBKSzVyPUGuNVUzOjlizszN NF7Ne2JUSU6JRWK=
H4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PEeGlEPTB;MT6xOVQ{QSEQvF2= M2j2XnNCVkeHUh?=
TUR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K5[WlEPTB;MT6xOVc2OiEQvF2= NHj4bmpUSU6JRWK=
NCI-H2141 M1HmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XQTWlEPTB;MT6xPFk1PiEQvF2= NF[3R|FUSU6JRWK=
PFSK-1 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\1fWlEPTB;MT6yNFU{OiEQvF2= NHznbpJUSU6JRWK=
SK-MEL-28 M3LC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwMkOyNlEh|ryP MlHCV2FPT0WU
SCC-9 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjuTWM2OD1zLkKzOlY2KM7:TR?= NVnnSo1[W0GQR1XS
T47D MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULLW2NyUUN3ME2xMlI{Pjl4IN88US=> MWrTRW5ITVJ?
TCCSUP MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTqTWM2OD1zLkK1NFI6KM7:TR?= MYnTRW5ITVJ?
SU-DHL-1 NUTaeW86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrmUWFKSzVyPUGuNlUyOThizszN M{TBZXNCVkeHUh?=
HL-60 NHjiU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rlS2lEPTB;MT6yOVU5QCEQvF2= M37CeHNCVkeHUh?=
NCI-H1436 M1SyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK2[FNKSzVyPUGuNlYyPDlizszN NGnQ[o1USU6JRWK=
DMS-114 M4TrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\NSmlEPTB;MT6yOlY{OiEQvF2= NWLUNYptW0GQR1XS
BOKU MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwMkiwPVUh|ryP Mkf3V2FPT0WU
MS-1 NIfvbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrWTWM2OD1zLkK5NFY6KM7:TR?= M3flfXNCVkeHUh?=
NCI-H661 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPiUpBKSzVyPUGuN|A1PzhizszN MUDTRW5ITVJ?
HT-3 M3vZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TmdWlEPTB;MT6zNFUzQSEQvF2= M2HpdnNCVkeHUh?=
CAL-54 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXmWnZKSzVyPUGuN|A4OjVizszN MX7TRW5ITVJ?
SW1463 M{XCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDwOppCUUN3ME2xMlMyQDd{IN88US=> MoLFV2FPT0WU
COLO-668 M2\ITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwM{OwOVYh|ryP NHzJZWFUSU6JRWK=
PANC-08-13 M3fHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnlR2gzUUN3ME2xMlM{QDB|IN88US=> MWDTRW5ITVJ?
BB49-HNC MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\hW4ZvUUN3ME2xMlM1ODFizszN NHXHZ45USU6JRWK=
M059J MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXWSVhKSzVyPUGuN|U5OzJizszN NWXWeYlRW0GQR1XS
NCCIT NXLpTlZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPKTWM2OD1zLkO3PVg5KM7:TR?= NGi2[49USU6JRWK=
LN-405 NHrxeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwM{myOlQh|ryP MV\TRW5ITVJ?
UMC-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7DTIhKSzVyPUGuN|k6QTZizszN M3PNPHNCVkeHUh?=
NB5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPFZY1zUUN3ME2xMlQyOjJ5IN88US=> NYG4V3VSW0GQR1XS
TE-441-T MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfmbIRKSzVyPUGuOFI5OTdizszN MnTvV2FPT0WU
ME-180 NIXSS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe3V2dKSzVyPUGuOFQ{QTJizszN NYLMdJJoW0GQR1XS
HCC70 NVz4OI02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n0[GlEPTB;MT60OlA6PiEQvF2= MY\TRW5ITVJ?
no-10 MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PaNWlEPTB;MT60OlE5OSEQvF2= NXnoXlFTW0GQR1XS
JEG-3 NUjoXnJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrXe45wUUN3ME2xMlUxOTN{IN88US=> M{jMRXNCVkeHUh?=
no-11 M{fVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LZUGlEPTB;MT61NFg5OiEQvF2= NHix[2FUSU6JRWK=
CHP-126 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwNU[2PVEh|ryP MnrDV2FPT0WU
EGI-1 M2rLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[yTWM2OD1zLkW4NFI2KM7:TR?= NHzkd2xUSU6JRWK=
D-392MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwNUm2N{DPxE1? MWfTRW5ITVJ?
RT4 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwNUm2N|ch|ryP M4\J[XNCVkeHUh?=
A204 Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\hNpNKSzVyPUGuOVk5ODFizszN NF33R2ZUSU6JRWK=
NCI-H1304 NYHkboRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwNkO1PVEh|ryP NIn3SIFUSU6JRWK=
Becker MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rxb2lEPTB;MT62OFI1OSEQvF2= MXnTRW5ITVJ?
OE19 M4O2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCNGRpUUN3ME2xMlY2PTF6IN88US=> NYH2[mFjW0GQR1XS
EKVX MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILHcolKSzVyPUGuOlU3OThizszN MWTTRW5ITVJ?
KLE NG[5XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInkTWFKSzVyPUGuOlU4OTRizszN NHnNV2RUSU6JRWK=
K-562 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLKTWM2OD1zLk[3NFM4KM7:TR?= NU\NTXFoW0GQR1XS
MDA-MB-175-VII NG\1epVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwNki5PVch|ryP MWDTRW5ITVJ?
NCI-H716 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG3NI13UUN3ME2xMlY6OzB2IN88US=> M3[zTnNCVkeHUh?=
Caov-3 NIXXPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnSe4NqUUN3ME2xMlY6PDF|IN88US=> MV\TRW5ITVJ?
HCC1187 NW\CS45yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HUcmlEPTB;MT63NFU1PSEQvF2= M3LibHNCVkeHUh?=
CAKI-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2raSWlEPTB;MT63NlI6OiEQvF2= MmDsV2FPT0WU
MOLT-16 NYL0ZZp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG3VGdlUUN3ME2xMlc{OzB5IN88US=> NWrDWYR[W0GQR1XS
PC-3 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwN{WwPEDPxE1? NFvWNZpUSU6JRWK=
DV-90 M3rhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jMNGlEPTB;MT63OVU5PSEQvF2= NYrVNHcxW0GQR1XS
RXF393 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVflTXg5UUN3ME2xMlc4Ojl2IN88US=> M4rGcHNCVkeHUh?=
SK-NEP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfmTWM2OD1zLkiyN|M6KM7:TR?= NF:5VWlUSU6JRWK=
HCC1419 NFq0SVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwOEK2PVIh|ryP NWL2PWtjW0GQR1XS
BV-173 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PkSGlEPTB;MT64Nlk6PSEQvF2= NVTr[HA2W0GQR1XS
MKN7 NX;oVXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X2fGlEPTB;MT64PVIzKM7:TR?= NXTIZ252W0GQR1XS
LAN-6 NHi4TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr5e5dxUUN3ME2xMlg6PTV|IN88US=> MUjTRW5ITVJ?
Mo-T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILjOW9KSzVyPUGuPVAxOzlizszN MWHTRW5ITVJ?
HCC1395 NX6xbGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofKTWM2OD1zLkmyPFY{KM7:TR?= MWDTRW5ITVJ?
HC-1 NVrmbYg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjnSYhKSzVyPUGuPVM1PyEQvF2= MoHYV2FPT0WU
HPAF-II MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvaZ3pKSzVyPUGuPVQ1OThizszN MWPTRW5ITVJ?
CPC-N NV[xdpZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvHTWM2OD1zLkm4NFAzKM7:TR?= M4\jVHNCVkeHUh?=
MKN45 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i4eWlEPTB;MT65PVEyQSEQvF2= MkfNV2FPT0WU
NCI-H1693 NEjXeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjjO5lKSzVyPUKuNFA1OzNizszN MVPTRW5ITVJ?
SHP-77 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PqOGlEPTB;Mj6wNFU{OyEQvF2= M2O1N3NCVkeHUh?=
NCI-H1522 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLmRYlKSzVyPUKuNFE4OjRizszN NXzGNWo1W0GQR1XS
SW1573 NEjYXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PhSGlEPTB;Mj6wNlIh|ryP NFS0XIdUSU6JRWK=
DBTRG-05MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPMTWM2OD1{LkC2NFg4KM7:TR?= M2XEPXNCVkeHUh?=
SCC-4 NEDVXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7sRWtRUUN3ME2yMlE1OzFizszN MVXTRW5ITVJ?
DMS-153 Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\XcpNKSzVyPUKuNVY3PjhizszN NFnLNndUSU6JRWK=
MDA-MB-415 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC5cYY5UUN3ME2yMlE4PTJizszN NF;qVGdUSU6JRWK=
NCI-H2126 NYjZZ|RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwMkK4PFgh|ryP NV;weZhGW0GQR1XS
MDA-MB-453 NFy2VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfLXnJKSzVyPUKuNlM{OiEQvF2= MYDTRW5ITVJ?
U-87-MG MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXITWM2OD1{LkK4OVkzKM7:TR?= MoCwV2FPT0WU
LNCaP-Clone-FGC NFXNWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJwM{CxNFIh|ryP M2WzPHNCVkeHUh?=
NCI-H1581 NHnTVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\kXHBIUUN3ME2yMlMzOTB3IN88US=> MmDoV2FPT0WU
BC-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjVe21KSzVyPUKuN|Y2ODlizszN Ml[wV2FPT0WU
HCC38 MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H4TWlEPTB;Mj6zPFQ1PyEQvF2= NXno[YFWW0GQR1XS
HCC2218 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXDSlNKSzVyPUKuOFA5ODlizszN MYrTRW5ITVJ?
RO82-W-1 NHfEU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjVZlVKSzVyPUKuOFEzPSEQvF2= MkO2V2FPT0WU
C2BBe1 NVzrdYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPPTWM2OD1{LkSxOVc5KM7:TR?= NWHVfIwyW0GQR1XS
LAMA-84 M3PJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW4d4pQUUN3ME2yMlU4OzZ6IN88US=> MoezV2FPT0WU
GMS-10 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;PTWM2OD1{LkW3OlEyKM7:TR?= NXy2ZZRjW0GQR1XS
GCT M1fHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\zbo9KSzVyPUKuOVg3QTRizszN M2r1bnNCVkeHUh?=
SK-CO-1 NGjvd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q0OGlEPTB;Mj62NVY3KM7:TR?= MV\TRW5ITVJ?
NCI-H526 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHQe4F1UUN3ME2yMlY{PDVizszN MWXTRW5ITVJ?
SW1088 M1ryVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO1TWM2OD1{Lke3PFM6KM7:TR?= MnrXV2FPT0WU
HT55 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwN{i2PVUh|ryP NF;ENW1USU6JRWK=
NB10 M{TU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2wTWM2OD1{LkixO|Q5KM7:TR?= M4XwcHNCVkeHUh?=
UACC-893 NFf0dY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\NTWM2OD1{Lki1O|Q6KM7:TR?= M2m0Z3NCVkeHUh?=
NCI-H1618 NHP2epdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO3XIJLUUN3ME2yMlg5OTV|IN88US=> NVvadFFEW0GQR1XS
NCI-H1092 NIPtdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jSfGlEPTB;Mz6wO|gyOiEQvF2= M4C1VnNCVkeHUh?=
SBC-1 NFvLWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDpTWM2OD1|LkC4OVU{KM7:TR?= NHX1e41USU6JRWK=
NCI-H1623 NHLkd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvVTWM2OD1|LkC5N|Qh|ryP NXnNWWdnW0GQR1XS
SiHa NWHiW45NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH0NoN[UUN3ME2zMlEyQTd5IN88US=> MmfWV2FPT0WU
D-263MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMUS3PFgh|ryP MUHTRW5ITVJ?
NCI-H1573 Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[5NXdKSzVyPUOuNVk3PDFizszN MVHTRW5ITVJ?
NCI-H82 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHiWHJKSzVyPUOuN|Q1OzlizszN NGLXfpBUSU6JRWK=
NCI-H2196 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC3TWM2OD1|LkO1NFA5KM7:TR?= NVjheldoW0GQR1XS
MFM-223 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNwM{ezOVEh|ryP MonGV2FPT0WU
COLO-678 NYrEeIlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonhTWM2OD1|LkO4NVg3KM7:TR?= NW[0XpBVW0GQR1XS
EW-3 M4O3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTNwNEC5OUDPxE1? NGPlNIVUSU6JRWK=
MHH-NB-11 NUHkRpR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrISVBjUUN3ME2zMlQ1ODZ7IN88US=> NVrNNFBKW0GQR1XS
EM-2 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwNkO5PEDPxE1? MmrMV2FPT0WU
FTC-133 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNwNkW0OVgh|ryP NH7UNJlUSU6JRWK=
NCI-H209 M2foOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M376WGlEPTB;Mz62O|Y2OyEQvF2= NHPKfVVUSU6JRWK=
TGBC24TKB Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke4TWM2OD1|Lk[4N|U2KM7:TR?= MnLCV2FPT0WU
LC-1F NHjuWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTNwN{G3OlQh|ryP NHe0WIRUSU6JRWK=
C-4-II M{jkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNwN{W2OFMh|ryP NF3VeYdUSU6JRWK=
NCI-H1650 NF7SWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WwSGlEPTB;Mz63PFQ2PSEQvF2= NES4V3VUSU6JRWK=
JVM-2 NVPVU2xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;qTWM2OD1|LkmzOlM6KM7:TR?= NYn1R25jW0GQR1XS
CaR-1 M2O1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq1e3dMUUN3ME2zMlk4PjF5IN88US=> NH3OcZhUSU6JRWK=
MDA-MB-134-VI MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXSdIRKSzVyPUSuNFI6PTJizszN MlnnV2FPT0WU
NCI-H719 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIeyW4dKSzVyPUSuNVU{QDhizszN NIjnVFNUSU6JRWK=
GOTO NEjWUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\PTWM2OD12LkK5O|A2KM7:TR?= NWXQdYhrW0GQR1XS
NCI-N87 NHjGXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRwM{i4NlEh|ryP NV3GUJJUW0GQR1XS
NB6 NXv0dGZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2zW|ZKSzVyPUSuOFI2ODlizszN NGOxSolUSU6JRWK=
DSH1 NW\QU3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojFTWM2OD12LkS3NVE3KM7:TR?= M1XRW3NCVkeHUh?=
BT-20 M1HYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L1UmlEPTB;ND60PVAxOiEQvF2= NG\YRWlUSU6JRWK=
NCI-H1882 NED3dGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[3TWM2OD12LkWwOVch|ryP NWX2NHR[W0GQR1XS
WM-115 NVLnSoJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTRwNUC4PFEh|ryP MonQV2FPT0WU
SKG-IIIa MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrqZWFKSzVyPUSuOlc4PyEQvF2= MonEV2FPT0WU
NCI-H69 NFTRenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7XTWM2OD12LkewNlc2KM7:TR?= NUm3XmVGW0GQR1XS
MSTO-211H MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwOEO1OlUh|ryP M4XwXnNCVkeHUh?=
Mewo NUDxPINYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwOU[zNVMh|ryP MXHTRW5ITVJ?
GI-ME-N MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDMTWM2OD13LkCwOVA6KM7:TR?= Ml\sV2FPT0WU
T98G M3TKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3mTWM2OD13LkC2OVA5KM7:TR?= NETnRlRUSU6JRWK=
ECC4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojHTWM2OD13LkC5N|czKM7:TR?= Mo[wV2FPT0WU
EW-11 NGHNepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPhb|U5UUN3ME21MlE5ODl7IN88US=> M1HlSXNCVkeHUh?=
COLO-800 M1XS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\HOHlKSzVyPUWuNVk{PDlizszN MYrTRW5ITVJ?
NCI-H1755 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX23UGE3UUN3ME21MlI{ODJ5IN88US=> M3[ybnNCVkeHUh?=
KMS-12-PE M2iyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTVwM{WwPFUh|ryP NW\Y[|c2W0GQR1XS
HCC1954 NXyybXR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HZVmlEPTB;NT64OVk4OSEQvF2= NWfHPHNlW0GQR1XS
NCI-H187 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFeyXWFKSzVyPUWuPVI6QDlizszN MUjTRW5ITVJ?
LU-165 NI\B[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPUelN7UUN3ME21Mlk6ODB{IN88US=> NYjiU2pTW0GQR1XS
YAPC M{nkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTVwOUmwOlgh|ryP Mmj2V2FPT0WU
LU-139 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTMXph7UUN3ME22MlA5OzZ6IN88US=> MUPTRW5ITVJ?
D-502MG NG\MSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe4e2ZKSzVyPU[uN|IxPDdizszN NUDZW3lHW0GQR1XS
IST-SL1 NVvuR2d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm1PJBPUUN3ME22MlU{QTR6IN88US=> MlvvV2FPT0WU
DG-75 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCxZ5ZnUUN3ME22Mlg5Pzh4IN88US=> M17VSnNCVkeHUh?=
NCI-H1155 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPsTWM2OD14Lkm1OVgyKM7:TR?= NGqyRVVUSU6JRWK=
EFE-184 M174WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDyTWM2OD15LkOxOlk2KM7:TR?= NEjSWGFUSU6JRWK=
AsPC-1 NV;RVZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTdwNEi4NFch|ryP MoXLV2FPT0WU
SW948 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTCTWM2OD15LkW4N|k2KM7:TR?= MY\TRW5ITVJ?
NCI-H524 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{noVGlEPTB;OT61PFYzQCEQvF2= NVXXdZp5W0GQR1XS
KOSC-2 M{Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD0TWM2OD17Lk[yPFM1KM7:TR?= MmDKV2FPT0WU
T-24 M37rWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLVN5Z4UUN3ME25Mlk1PDF3IN88US=> NFXTWZBUSU6JRWK=
NCI-H748 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3vNoJKSzVyPUGwMlY{QTdizszN MkjzV2FPT0WU
NCI-H23 NWXSWWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFyLk[0OFIh|ryP MX7TRW5ITVJ?
UACC-812 NXjNWpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;KRoZSUUN3ME2xNU44OTdizszN MU\TRW5ITVJ?
SCLC-21H NGHye|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzwNFhKSzVyPUGyMlE2PTFizszN NGLMe21USU6JRWK=
NCI-SNU-16 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF|LkGyOVgh|ryP NWPN[VA2W0GQR1XS
HD-MY-Z MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3LbI9mUUN3ME2xOE43OzZ|IN88US=> MnjRV2FPT0WU
SK-N-FI Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[1W5V{UUN3ME2xOE45QTF{IN88US=> NIDOblBUSU6JRWK=
LB647-SCLC MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HxW2lEPTB;MUWuO|E6PSEQvF2= MWrTRW5ITVJ?
NCI-H345 NHjtWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHMWFZKUUN3ME2xO{4{PDNizszN MWfTRW5ITVJ?
NCI-H1563 NVHUd|RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF6Lke2NFEh|ryP NUjkZVVFW0GQR1XS
RL MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH3U4FNUUN3ME2yNU4zPjV4IN88US=> MlLLV2FPT0WU
KY821 NIi0b4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPMXZVKSzVyPUKyMlA2PTNizszN M{PzPXNCVkeHUh?=
JVM-3 M3TQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m4fmlEPTB;MkWuNFQyOyEQvF2= MYfTRW5ITVJ?
NCI-H1793 NVTGfI5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlryTWM2OD1{OD61OFk6KM7:TR?= NVr5fnVSW0GQR1XS
LU-134-A MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljvTWM2OD1|MD6yNFM4KM7:TR?= MWTTRW5ITVJ?
NCI-H1395 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G0UGlEPTB;M{KuNlQ{OSEQvF2= NXfX[nZ3W0GQR1XS
NCI-H1993 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTN{LkiyNVgh|ryP NEXKXYlUSU6JRWK=
P31-FUJ Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm1TFhmUUN3ME2zN{41QDl7IN88US=> NYH1Z3o5W0GQR1XS
LS-513 NHqxbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWxUW5LUUN3ME2zOU45QDd7IN88US=> Mlv2V2FPT0WU
SK-MEL-1 M{DjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRyLkO0PVkh|ryP NE\mTHVUSU6JRWK=
SW684 M4\yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP2TWM2OD12Mz65OlYyKM7:TR?= Mn7vV2FPT0WU
COR-L88 NVH3eXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTR2LkC2OlUh|ryP M3PMdnNCVkeHUh?=
NCI-H889 NUnB[G56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTWVnlvUUN3ME20OU4xODh5IN88US=> Mom2V2FPT0WU
TALL-1 NHjDSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS0WpM2UUN3ME20Ok4yOTl7IN88US=> MmG1V2FPT0WU
KARPAS-299 M4TyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XGUmlEPTB;NEeuNVk6OyEQvF2= MkjJV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Bcl-2 Binding affinity calculation:

A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:[2]
+ Expand
  • Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
  • Concentrations: ~10 μM
  • Incubation Time: 48-72 hours
  • Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
  • Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
  • Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg
  • Administration: Administered intravenously (tail vein) once a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.73 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2
NCT00724841 Terminated Metastatic Melanoma Gemin X|Teva Pharmaceutical Industries June 2008 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID